NCT02599922View on ClinicalTrials.gov

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 11, 2016

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2026

Conditions
Achromatopsia
Interventions
BIOLOGICAL

rAAV2tYF-PR1.7-hCNGB3

rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.

Trial Locations (8)

27710

Duke Eye Center, Duke University Medical Center, Durham

32607

VitreoRetinal Associates, Gainesville

33136

Bascom Palmer Eye Institute, Miami

45242

Cincinnati Eye Institute, Cincinnati

60608

Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp, Chicago

97239

Casey Eye Institute, Oregon Health and Sciences University, Portland

02114

Massachusetts Eye and Ear Infirmary, Boston

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

National Eye Institute (NEI)

NIH

lead

Beacon Therapeutics

INDUSTRY